Searchable abstracts of presentations at key conferences in endocrinology

ea0089o6 | Other | NANETS2022

Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings

A. Ramirez Robert , Koyama Tatsuki , Das Satya

Background: Pulmonary carcinoid (PC) tumors represent approximately 25% of neuroendocrine tumors (NETs) and about 2% of all lung cancers. Despite the relative prevalence of PCs compared to all NETs, there is only one FDA indicated therapy (everolimus). Since regulatory approvals stem from publications that are often initially presented at scientific meetings, we sought to determine the frequency of presentations including PCs at two major international NET and lung cancer meet...

ea0089t1 | Trials In Progress | NANETS2022

Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma

Stockton Shannon , Dan Ayers G. , Cecchini Michael , Ajumaily Raid , Whisenant Jennifer , Gore Steven , Ivy Percy , LoRusso Patricia , Berlin Jordan , Das Satya

Background: Advanced small cell lung cancer (SCLC), extra-pulmonary neuroendocrine carcinoma (EP-NEC) and pancreatic adenocarcinoma (PDA) are rapidly progressive cancers characterized by unbridled replication stress. Patients with these malignancies possess dismal prognoses with limited options after initial first-line chemotherapy. These tumors rely on the integrity of DNA damage repair pathways to ensure genomic stability. The ataxia telangiectasia and Rad3-related (ATR) pro...

ea0089t5 | Trials In Progress | NANETS2022

A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors

Jimenez Camilo , Hadoux Julien , Del Rivero Jaydira , Das Satya , Iliopoulos Othon , Sultanbaev Alexander , Artamonova Elena , Jonasch Eric , Pacak Karel , Wang Wei , Jin Fan , S. Naik Girish , Capdevila Jaume

Background: Patients with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (panNET) are in need of novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is one of the key oncogenic drivers in neuroendocrine tumors. Hypoxia signaling pathway alterations or other mechanisms that stabilize HIFs are common in some PPGLs and panNETs. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in advanced renal cell...